Phenytoin, levetiracetam, and pregabalin in the acute management of refractory status epilepticus in patients with brain tumors

Neurocritical Care

Volumn 16, Issue 1, 2012, Pages 109-113

  Swisher, Christa B ^a   Doreswamy, Meghana ^a   Gingrich, Krista J ^a   Vredenburgh, James J ^a   Kolls, Brad J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Brain tumor; Levetiracetam; Phenytoin; Pregabalin; Refractory status epilepticus; Status epilepticus

Indexed keywords

ETIRACETAM; MIDAZOLAM; PHENYTOIN; PREGABALIN; TOPIRAMATE; VALPROIC ACID;

ADULT; ARTICLE; BRAIN TUMOR; CLINICAL ARTICLE; DISEASE CONTROL; DRUG BLOOD LEVEL; DRUG CHOICE; EPILEPTIC STATE; FEMALE; HUMAN; MALE; METASTASIS POTENTIAL; MORTALITY; PRIMARY TUMOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ACUTE DISEASE; AGED; ANTICONVULSANTS; BRAIN NEOPLASMS; DRUG THERAPY, COMBINATION; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; PHENYTOIN; PIRACETAM; RETROSPECTIVE STUDIES; STATUS EPILEPTICUS; TREATMENT OUTCOME;

EID: 84860681621     PISSN: 15416933     EISSN: 15560961     Source Type: Journal    
DOI: 10.1007/s12028-011-9626-4     Document Type: Article

References (22)

1. Porter KR, et al. Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro Oncol. 2010; 12(6): 520-7.
2. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia. 1993; 34(3): 453-68.
3. Morris HH, et al. Chronic intractable epilepsy as the only symptom of primary brain tumor. Epilepsia. 1993; 34(6): 1038-43. (Pubitemid 24004241)
4. Hildebrand J, et al. Epileptic seizures during follow-up of patients treated for primary brain tumors. Neurology. 2005; 65(2): 212-5. (Pubitemid 41022363)
5. Moots PL, et al. The course of seizure disorders in patients with malignant gliomas. Arch Neurol. 1995; 52(7): 717-24.
6. Aminoff MJ, Simon RP. Status epilepticus. Causes, clinical features andconsequencesin98patients.AmJMed.1980; 69(5): 657-66.
7. DeLorenzo RJ, et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology. 1996; 46(4): 1029-35.
8. KnakeS, et al. Incidence of status epilepticus in adults in Germany: A prospective population-basedstudy. Epilepsia.2001; 42(6): 714-8. (Pubitemid 32605930)
9. Sagduyu A, Tarlaci S, Sirin H. Generalized tonic-clonic status epilepticus: causes, treatment, complications and predictors of case fatality. J Neurol. 1998; 245(10): 640-6. (Pubitemid 28439028)
10. Claassen J, et al. Predictors of functional disability and mortality after status epilepticus. Neurology. 2002; 58(1): 139-42. (Pubitemid 34041954)
11. Towne AR, et al. Determinants of mortality in status epilepticus. Epilepsia. 1994; 35(1): 27-34. (Pubitemid 24074462)
12. Fountain NB. Status epilepticus: risk factors and complications. Epilepsia. 2000; 41(Suppl 2): S23-30. (Pubitemid 30387358)
13. Claassen J, Hirsch LJ, Mayer SA. Treatment of status epilepticus: A survey of neurologists. J Neurol Sci. 2003; 211(1-2): 37-41. (Pubitemid 36593265)
14. Lowenstein DH, Alldredge BK. Status epilepticus. N Engl J Med. 1998; 338(14): 970-6. (Pubitemid 28152839)
15. Knake S, et al. Intravenous levetiracetam in the treatment of benzodiazepine refractory status epilepticus. J Neurol Neurosurg Psychiatry. 2008; 79(5): 588-9. (Pubitemid 351571881)
16. Moddel G, et al. Intravenous levetiracetam: A new treatment alternative for refractory status epilepticus. J Neurol Neurosurg Psychiatry. 2009; 80(6): 689-92.
17. Rossetti AO, Bromfield EB. Levetiracetam in the treatment of status epilepticus in adults: A study of 13 episodes. Eur Neurol. 2005; 54(1): 34-8. (Pubitemid 41328732)
18. Gaitanis JN, Drislane FW. Status epilepticus: A review of different syndromes, their current evaluation, and treatment. Neurologist. 2003; 9(2): 61-76. (Pubitemid 36378611)
19. Novy J, Rossetti AO. Oral pregabalin as an add-on treatment for status epilepticus. Epilepsia. 2010; 51(10): 2207-10.
20. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004; 45(Suppl 6): 13-8. (Pubitemid 39350325)
21. Cranford RE, et al. Intravenous phenytoin: clinical and pharmacokinetic aspects. Neurology. 1978; 28(9 Pt 1): 874-80. (Pubitemid 8390039)
22. Lynch BA, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA. 2004; 101(26): 9861-6. (Pubitemid 38869327)